Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Revises Guidance on DMFs and Prior Approval Supplements to Reflect GDUFA II

Executive Summary

FDA has revised references in guidance to generic drug user fee requirements that changed under GDUFA II on Oct. 1. One guidance document no longer says for generics firms to pay user fees for prior approval supplement reviews. Another gives review goals for drug master file completeness assessments.

Advertisement

Related Content

Generic Sponsors Need To Increase Communications About Drug Master Files, US FDA Says
FDA Outlines Criteria For Approving Manufacturing Supplements Under GDUFA
US FDA Clarifies Expectations For Completeness Assessments For Drug Master Files
FDA Clarifies Expectations for Completeness Assessments for Drug Master Files

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS121743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel